Brokerages Anticipate G1 Therapeutics Inc (GTHX) Will Post Earnings of -$0.67 Per Share

Equities research analysts expect that G1 Therapeutics Inc (NASDAQ:GTHX) will announce earnings per share (EPS) of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for G1 Therapeutics’ earnings, with estimates ranging from ($0.72) to ($0.64). G1 Therapeutics posted earnings of ($0.55) per share during the same quarter last year, which suggests a negative year over year growth rate of 21.8%. The firm is expected to announce its next earnings results on Wednesday, November 14th.

According to Zacks, analysts expect that G1 Therapeutics will report full year earnings of ($2.66) per share for the current financial year, with EPS estimates ranging from ($2.75) to ($2.55). For the next financial year, analysts expect that the business will report earnings of ($2.94) per share, with EPS estimates ranging from ($3.13) to ($2.72). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.01.

GTHX has been the topic of a number of research analyst reports. BidaskClub lowered shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 27th. Needham & Company LLC raised their price objective on shares of G1 Therapeutics to $76.00 and gave the stock a “buy” rating in a report on Tuesday, September 18th. HC Wainwright restated a “buy” rating and set a $79.00 price objective on shares of G1 Therapeutics in a report on Monday, September 17th. BTIG Research initiated coverage on shares of G1 Therapeutics in a report on Monday, September 10th. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. G1 Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $74.50.

In other G1 Therapeutics news, insider Jay Strum sold 10,000 shares of G1 Therapeutics stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $59.60, for a total value of $596,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark A. Velleca sold 5,000 shares of G1 Therapeutics stock in a transaction on Monday, July 16th. The shares were sold at an average price of $42.06, for a total transaction of $210,300.00. The disclosure for this sale can be found here. Insiders sold a total of 66,583 shares of company stock worth $3,617,196 over the last quarter. Company insiders own 15.92% of the company’s stock.

A number of hedge funds have recently modified their holdings of GTHX. Cubist Systematic Strategies LLC grew its position in shares of G1 Therapeutics by 484.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock valued at $104,000 after acquiring an additional 2,316 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of G1 Therapeutics by 58.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after acquiring an additional 1,045 shares during the period. Great West Life Assurance Co. Can grew its position in shares of G1 Therapeutics by 148.3% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after acquiring an additional 1,560 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its position in shares of G1 Therapeutics by 44.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after acquiring an additional 1,200 shares during the period. Finally, Strs Ohio grew its position in shares of G1 Therapeutics by 78.3% in the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after acquiring an additional 1,800 shares during the period. Hedge funds and other institutional investors own 69.17% of the company’s stock.

Shares of NASDAQ:GTHX traded down $0.02 during midday trading on Friday, reaching $42.98. 279,513 shares of the company were exchanged, compared to its average volume of 278,142. G1 Therapeutics has a fifty-two week low of $18.03 and a fifty-two week high of $69.57. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -12.04 and a beta of -1.02.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Article: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply